Stock Evaluator: Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. AQST

$3.76 -0.15 -3.84%
November 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,999,965
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company’s proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Commentary & Analysis


Financial Summary

Share Statistics AQST Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $472.6 $433.9 38%
Shares Out (Mil) 125.5 46.5 66%
Institutional Ownership 92.9% 82.2% 62%
Float (Mil) 113.2 47.7 63%
Beta 1.50 0.74 82%
Avg Daily Volume (000s) 3,058 345 85%
Price Change
(52-week)
(29.1%) 52.0% 31%
Growth AQST Industry
Median
Percentile
(All Stocks)
Sales (5yr) (0.6%) 6.4% 16%
Net Income (5yr) (8.5%) (1.6%) 31%
EPS (5yr) 13.9% 15.1% 54
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 23.6% (15.1%) 82%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($0.110) ($0.400) ($0.580)
Month Ago EPS ($0.140) ($0.450) ($0.570)
# Rev Up 0 2 2
# Rev Down 0 0 0
Three Months Ago EPS ($0.140) ($0.450) ($0.570)
Year/Year Chg (16.0%) (49.0%) (67.5%)
Financials AQST Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $49 $289 19%
Net Income (TTM) (Mil) ($79) ($11) 13%
EPS (TTM) ($0.640) ($0.600) 24%
Operating Cash Flow (TTM) (Mil) ($40) ($7) 11%
Net Cash Flow (TTM) (Mil) ($39) $1 23%
Long-Term Debt (Q1) (Mil) $58 $6 40%
Enterprise Value (Q1) (Mil) $446 $331 33%
Valuation AQST Industry
Median
Percentile
(All Stocks)
P/B na 2.05 na
P/E na 24.3 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios AQST Industry
Median
Percentile
(All Stocks)
Gross Margin 65.3% 69.5% 78%
Net Margin (162.3%) 3.9% 6%
ROA (56.0%) (23.3%) 10%
ROE 211.6% (21.8%) 98%
Liabilities to Assets 159.4% 31.2% 98%
F-Score 4 3 33%

Aquestive Therapeutics, Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors